Ibuprofen - Oxford Pharmascience

Drug Profile

Ibuprofen - Oxford Pharmascience

Alternative Names: Ibuprofen oral suspension - Oxford Pharmascience; Ibuprofen-layered double hydroxide; Ibuprofen-LDH; OXP 001; OXP 002; OXProfen; OXPzero™ Ibuprofen; Reduced gastric irriation ibuprofen; Taste-masked ibuprofen suspension

Latest Information Update: 27 Dec 2016

Price : $50

At a glance

  • Originator Oxford Pharmascience
  • Class Antirheumatics; Nonsteroidal anti-inflammatories; Phenylpropionates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Musculoskeletal pain

Most Recent Events

  • 01 Dec 2016 Oxford Pharmascience initiates a phase I pharmacokinetics trial of ibuprofen-LDH in Healthy volunteers in United Kingdom (PO) (NCT02974361)
  • 22 Nov 2016 Oxford Pharmascience plans a phase I pharmacokinetics trial of ibuprofen-LDH in Healthy volunteers in United Kingdom (PO) (NCT02974361)
  • 09 Nov 2016 Oxford Pharmascience's ibuprofen is available for market licensing as of 09 Nov 2016. www.oxfordpharmascience.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top